Messing, M
When choosing among them, factors such as glycemic efficacy, weight effects and patient preferences may take precedence over concerns about major differences in [GI] risk. She added clinicians should continue to monitor for GI symptoms, particularly early in treatment, as these events, while uncommon, remain more frequent than with some other diabetes drug classes. According to Alkabbani and colleagues, recent trials revealed that dulaglutide (Trulicity, Eli Lilly), semaglutide (Ozempic/Wegovy, Novo Nordisk) and tirzepatide (Zepbound, Eli Lilly) increased the risk for mild to serious GI adverse events like pancreatitis, constipation, nausea, vomiting and biliary disease
Additionally, the lipid content of any food item is considered as one of the important aspects of itsnutritional value, andseveral food types have different levels oflipid contents, including triacylglycerols, polar lipids, free fatty acids, or diacylglycerols
The $100 Billion Weight Loss Drug War Has Officially Started Patents are expiring
See RedCrossBlood.org/March for details